EDNRB and pulmonary arterial hypertension: In 1990, two receptors of ET-1 were identified, type A (ETA) and type B (ETB), respectively, offering the foundation for designing Bosentan (an antagonist of the ET-1 receptor), which can be currently used in the treatment of patients with pulmonary arterial hypertension.